for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aileron Therapeutics Inc

ALRN.OQ

Latest Trade

0.45USD

Change

0.00(0.00%)

Volume

36,786

Today's Range

0.42

 - 

0.49

52 Week Range

0.40

 - 

2.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aileron - On Track To Announce Final Data Readout For Clinical Trial Of Alrn-6924 In Q2 Of 2020

Nov 7 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS INC - ON TRACK TO ANNOUNCE FINAL DATA READOUT FOR CLINICAL TRIAL OF ALRN-6924 IN Q2 OF 2020.AILERON THERAPEUTICS INC - QTRLY ADJUSTED. NET LOSS PER SHARE $0.28.AILERON THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF SEPTEMBER 30, 2019 WERE $24.6 MILLION.

Aileron Therapeutics Announces Initiation Of Patient Treatment In First Clinical Ph1b/2 Trial Of Alrn-6924

Oct 16 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS ANNOUNCES THE INITIATION OF PATIENT TREATMENT IN ITS FIRST CLINICAL PH1B/2 TRIAL OF ALRN-6924 AS A MYELOPRESERVATION AGENT.AILERON THERAPEUTICS INC - MANAGEMENT PLANS TO EXPAND ITS ONGOING CLINICAL MYELOPRESERVATION TRIAL TO INCLUDE TWO ADDITIONAL COHORTS.AILERON THERAPEUTICS INC - EXPECTS TO PRESENT KEY FINDINGS OF PHASE 1B PORTION OF MYELOPRESERVATION TRIAL IN Q2 2020.AILERON THERAPEUTICS INC - IN ONGOING PHASE 1B TRIAL, PATIENT ENROLLMENT INTO 2 NEW COHORTS IS EXPECTED TO COMMENCE IN Q2 OF 2020.AILERON THERAPEUTICS INC - PLANS TO REALLOCATE RESOURCES FROM EARLY-STAGE PIPELINE PROGRAMS TO INVEST INTO CLINICAL DEVELOPMENT OF ALRN-6924.

Aileron Therapeutics Announces Management Change

Sept 9 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS ANNOUNCES MANAGEMENT CHANGE.AILERON THERAPEUTICS INC - DON DOUGHERTY, ITS CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING AILERON EFFECTIVE SEPTEMBER 13, 2019.AILERON THERAPEUTICS INC - DON DOUGHERTY, ITS CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING AILERON EFFECTIVE SEPTEMBER 13.AILERON THERAPEUTICS INC - DON DOUGHERTY, ITS CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING AILERON EFFECTIVE SEPTEMBER 13, 2019.AILERON THERAPEUTICS INC - ALL FINANCIAL RESPONSIBILITIES ARE BEING TRANSITIONED TO RICHARD WANSTALL.

Aileron Therapeutics Reports Q2 2019 Results

Aug 6 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.26.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019 WERE $31.5 MILLION, COMPARED TO $20.7 MILLION AS OF DECEMBER 31, 2018.

Aileron Therapeutics - On July 12 Received Deficiency Letter From Listing Qualifications Department Of Nasdaq

July 15 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS - ON JULY 12 RECEIVED DEFICIENCY LETTER FROM LISTING QUALIFICATIONS DEPARTMENT OF NASDAQ STOCK MARKET.AILERON THERAPEUTICS - DEFICIENCY LETTER NOTIFIED BID PRICE FOR CO'S STOCK CLOSED BELOW MINIMUM REQUIREMENT FOR CONTINUED INCLUSION ON NASDAQ GLOBAL MARKET.AILERON THERAPEUTICS - DEFICIENCY LETTER DOES NOT RESULT IN IMMEDIATE DELISTING OF CO'S COMMON STOCK FROM NASDAQ GLOBAL MARKET.AILERON THERAPEUTICS - CO HAS BEEN PROVIDED INITIAL PERIOD OF 180 CALENDAR DAYS TO REGAIN COMPLIANCE WITH BID PRICE RULE.

Aileron Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

June 27 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND FOR ALRN-6924 AS A MYELOPRESERVATION AGENT IN PATIENTS WITH P53-MUTANT CANCER TREATED WITH CHEMOTHERAPY.AILERON THERAPEUTICS INC - COMPANY EXPECTS TO ENROLL UP TO 40 PATIENTS IN PHASE 1B PORTION OF PLANNED PHASE 1B/2 TRIAL FOR ALRN-6924.

Aileron Therapeutics Updated Information On Design, Anticipated Timing Of Data From Its Ongoing Alrn-6924 Trials

June 5 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS - UPDATED INFORMATION ON DESIGN, ANTICIPATED TIMING OF DATA FROM ITS ONGOING, PLANNED CLINICAL ALRN-6924 TRIALS.AILERON THERAPEUTICS INC - CONDUCTING A PHASE 2A CLINICAL TRIAL OF COMBINATION OF ALRN-6924 AND PALBOCICLIB (IBRANCE), MARKETED BY PFIZER.AILERON THERAPEUTICS INC - TO HAVE FINAL DATA FROM ALL 25 PATIENTS IN ALRN-6924 TRIAL IN Q2 OF 2020.AILERON THERAPEUTICS INC - PLANS TO DISCLOSE DATA FROM PHASE 1B PORTION OF MYELOPRESERVATION TRIAL IN Q2 OF 2020.

Aileron Therapeutics Reports Q1 Loss Per Share Of $0.49

May 8 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.

Armistice Capital Reports 8 Pct Passive Stake In Aileron Therapeutics Inc As Of March 29

April 8 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::ARMISTICE CAPITAL LLC REPORTS 8.0 PERCENT PASSIVE STAKE IN AILERON THERAPEUTICS INC AS OF MARCH 29 - SEC FILING.

Aileron Therapeutics Announces Pricing Of $26 Mln Private Placement

March 29 (Reuters) - Aileron Therapeutics Inc <ALRN.O>::AILERON THERAPEUTICS ANNOUNCES PRICING OF $26M PRIVATE PLACEMENT.AILERON THERAPEUTICS - ENTERED INTO SECURITIES PURCHASE DEAL WITH GROUP OF INSTITUTIONAL ACCREDITED INVESTORS OF $26 MILLION OF AILERON STOCK, WARRANTS.AILERON THERAPEUTICS - SELLING IN PRIVATE PLACEMENT 11.8 MILLION UNITS FOR A COMBINED PRICE OF $2.01 PER UNIT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up